Results 91 to 100 of about 42,703 (308)

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

Arthritis &Rheumatology, EarlyView.
Objective Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease‐modifying antirheumatic drugs with other modes of action (bDMARD‐OMA) in a multicountry, real‐world population ...
Romain Aymon, Denis Mongin, Romain Guemara, Zubeyir Salis, Johan Askling, Denis Choquette, Catalin Codreanu, Daniela Di Giuseppe, Irini Flouri, Doreen Huschek, Kimme L. Hyrich, Florenzo Iannone, Tore K. Kvien, Burkhard F. Leeb, Dan Nordström, Lucia Otero‐Varela, Karel Pavelka, Manuel Pombo‐Suarez, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Sella A. Provan, Anja Strangfeld, Trokovic Nina, Jakub Zavada, Lianne Kearsley‐Fleet, Delphine S. Courvoisier, Axel Finckh, Kim Lauper   +28 more
wiley   +1 more source

To the problem of extended serological testing for viral hepatitis B in rheumatoid arthritis patients

Терапевтический архив
Aim. The objectives of the study: to conduct serologic screening for latent HBV infection in rheumatoid arthritis (RA) patients, to determine the level of protective antibodies to HBsAg in RA patients, and to determine the clinical and laboratory ...
Galina I. Gridneva, Boris S. Belov, Zhanna G. Verizhnikova, Evgeniia S. Aronova, Elena Yu. Samarkina, Taras S. Panevin, Tatiana A. Lisitsyna, Galina V. Lukina   +7 more
doaj   +1 more source

Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]

, 2017
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K., Mantravadi, Santhi, Ogdie, Alexis   +2 more
core   +2 more sources

Comparative Analysis of Circulating and Synovial Immune Cells in Early Untreated Rheumatoid Arthritis and Their Relationship With Molecular Pathology and Disease Outcomes

Arthritis &Rheumatology, EarlyView.
Objective To assess the relationship of circulating and synovial immune cells with synovial molecular pathology and disease outcomes in patients with early rheumatoid arthritis (RA). Methods Patients with early (<12 months) treatment‐naive RA (n = 144) from the Pathobiology of Early Arthritis Cohort were included in this post hoc analysis.
Felice Rivellese, Elena Pontarini, Liliane Fossati‐Jimack, Rita A. Moura, Vasco C. Romão, João Eurico Fonseca, Alessandra Nerviani, Cankut Çubuk, Katriona Goldmann, Giovanni Giorli, Myles Lewis, Michele Bombardieri, Costantino Pitzalis, on behalf of the Pathobiology of Early Arthritis Cohort (PEAC) investigators   +13 more
wiley   +1 more source

Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis

Advances in Pharmacological Sciences, 2013
Methotrexate (MTX) is a nonbiological disease-modifying antirheumatic drug that has shown both a good control of clinical disease and a good safety. Usually drug-drug interactions (DDIs) represent the most limiting factor during the clinical management ...
Marinella Patanè, Miriam Ciriaco, Serafina Chimirri, Francesco Ursini, Saverio Naty, Rosa Daniela Grembiale, Luca Gallelli, Giovambattista De Sarro, Emilio Russo   +8 more
doaj   +1 more source

Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting. [PDF]

, 2014
Rheumatoid arthritis (RA) is an inflammatory autoimmune condition typified by systemic inflammation targeted toward synovial joints. Inhibition of proinflammatory networks by disease-modifying antirheumatic drugs, eg, methotrexate and biologic therapies,
Ahmed, S, Harrison, A, Magan, T, Sofat, N, Vargas, M   +4 more
core   +2 more sources

Chronic hepatitis B in rheumatic diseases: issues of screening and reactivation of infection: A review [PDF]

Терапевтический архив
Patients with rheumatic diseases infected with hepatitis B virus (HBV) are difficult to manage not only due to the presence of risk factors for the development and rapid progression of liver cirrhosis, but also due to the likelihood of reactivation of ...
Galina I. Gridneva, Boris S. Belov, Evgeniia S. Aronova   +2 more
doaj   +1 more source

A Review of Ankylosing Spondylitis [PDF]

, 2017
Ankylosing spondylitis (AS) is a systemic autoimmune disorder that induces ankylosis of the spine (fusion of the vertebrae at their various joints) and inflammatory arthritis of peripheral joints among other symptoms.
Owen, Hannah L
core   +1 more source

Mucosal‐Associated Invariant T Cells in Rheumatic Diseases

Arthritis &Rheumatology, EarlyView.
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek, Virginie Gonzalez, Lucie Beaudoin, Noémie Sénot, Corinne Miceli‐Richard, Yannick Allanore, Agnès Lehuen, Jerôme Avouac   +7 more
wiley   +1 more source

Kinase inhibitors: a new class of antirheumatic drugs

Drug Design, Development and Therapy, 2012
Vasileios C KyttarisDivision of Rheumatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USAAbstract: The outlook for patients with rheumatoid arthritis has improved significantly over the last three decades with the use
Kyttaris VC
doaj